Thorazine (Chlorpromazine): Clinical Overview
Indications
Thorazine is FDA-approved for multiple psychiatric and medical conditions, with schizophrenia and severe behavioral disorders being the primary psychiatric indications. 1
Psychiatric indications:
- Schizophrenia and psychotic disorders 1
- Severe behavioral problems in pediatric patients (6 months to 12 years) 1
- Presurgical apprehension 1
Medical indications:
- Nausea and vomiting 1
- Intractable hiccups 1
- Acute intermittent porphyria 1
- Tetanus (as adjunctive therapy) 1
Adult Dosing
Schizophrenia and Psychotic Disorders
For acute psychotic episodes, chlorpromazine should be dosed at a minimum therapeutic equivalent of 600 mg/day for at least 6 weeks to constitute an adequate treatment trial. 2
Oral dosing:
- Outpatients: Start with lower doses and titrate gradually based on response 1
- Hospitalized patients: Higher doses (50-100 mg daily initially, up to 200 mg or more in severe cases) may be necessary 1
- Maximum recommended: 500 mg/day for most patients, though some severely disturbed patients may require higher doses 1
Intramuscular dosing:
- Acute agitation: 25 mg IM initially; repeat with 25-50 mg in 1 hour if needed 1
- Subsequent doses: 25-50 mg IM every 3-4 hours until oral therapy can be initiated 1
Intravenous dosing (reserved for specific indications only):
- Severe hiccups, surgery, and tetanus: 25-50 mg diluted to at least 1 mg/mL, administered at 1 mg per minute 1
- Never inject undiluted chlorpromazine into a vein 1
Other Indications
Intractable hiccups:
- Oral: 25-50 mg three to four times daily 1
- IM: 25-50 mg if oral therapy fails after 2-3 days 1
- IV: 25-50 mg in 500-1000 mL saline as slow infusion with patient supine, monitoring blood pressure closely 1
Nausea and vomiting:
- IM: 25 mg initially; repeat every 3-4 hours as needed 1
Acute intermittent porphyria:
- IM: 25 mg three to four times daily until oral therapy possible 1
Contraindications
Chlorpromazine is contraindicated in comatose states and in the presence of large amounts of central nervous system depressants. 1
Key contraindications include:
- Comatose states 1
- Presence of large amounts of CNS depressants (alcohol, barbiturates, narcotics) 1
- Bone marrow suppression 1
- Hypersensitivity to phenothiazines 1
Special precautions:
- Pediatric use: Generally not recommended under 6 months of age except when potentially lifesaving 1
- Subcutaneous injection is not advised 1
Monitoring Parameters
Clinical Monitoring
Blood pressure monitoring is critical, especially with parenteral administration, as chlorpromazine causes significant hypotensive effects. 1
Essential monitoring includes:
- Blood pressure: Closely monitor during IV infusion and keep patients supine for at least 30 minutes after IM injection 1
- Extrapyramidal symptoms: Higher doses (> 400 mg/day) significantly increase risk 3
- Mental status and behavioral response: Assess at 4-6 week intervals to determine treatment adequacy 2
Pharmacokinetic Considerations
Chlorpromazine exhibits highly variable pharmacokinetics with extensive first-pass metabolism (bioavailability 4-38%) and wide inter-individual variability. 4
Key pharmacokinetic parameters:
- Half-life: Approximately 11 hours (range varies widely) 4
- Volume of distribution: 1215 L (highly variable) 4
- Systemic clearance: 76.6 L/h 4
- Lung concentration: 20-200 times higher than plasma 5
- Saliva concentration: 30-100 times higher than plasma 5
Adverse Effect Monitoring
Extrapyramidal symptoms occur significantly more frequently at medium doses (401-800 mg/day) compared to low doses (≤400 mg/day). 3
Monitor for:
- Extrapyramidal symptoms (parkinsonism, akathisia, dystonia): Risk increases dose-dependently, particularly above 400 mg/day 3
- Sedation and orthostatic hypotension: Common, especially with parenteral administration 1
- Contact dermatitis: Avoid getting solution on hands or clothing 1
- Seizures: Risk increases at higher doses 6
Dosing in Treatment-Resistant Schizophrenia
Chlorpromazine serves as the reference standard for antipsychotic dose equivalency, with 600 mg/day representing the minimum therapeutic dose for adequate treatment trials. 2, 7
Treatment resistance criteria require:
- Failure of at least two adequate trials with different antipsychotics 2
- Each trial lasting at least 6 weeks at therapeutic dose (≥600 mg chlorpromazine equivalents) 2
- Good adherence documented (ideally including one long-acting injectable trial) 2
After two failed adequate trials, clozapine should be considered rather than escalating chlorpromazine doses. 6
Important Clinical Pearls
The optimal dose range for chlorpromazine is ≤400 mg/day, as higher doses significantly increase extrapyramidal side effects without proportional clinical benefit. 3
Route-specific considerations:
- IM injections: Deep into upper outer quadrant of buttock; may dilute with saline or 2% procaine if irritation occurs 1
- IV administration: Reserved only for severe hiccups, surgery, and tetanus—never for routine psychiatric use 1
- Inspect all parenteral solutions for particulate matter before administration 1
Pediatric dosing differs substantially from adults, with children requiring higher mg/kg doses to achieve similar plasma levels and having lower response thresholds for both efficacy and toxicity. 8